Trial reportClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2013
Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight.
Trial report in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00976443 (Physiologic Effects of High-Dose Gastric Antral Botulinum Toxin Injections), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Physiologic Effects of High-Dose Gastric Antral Botulinum Toxin Injections
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Intragastric Botulinum Toxin A Injection Is an Effective Obesity Therapy for Patients with BMI > 40 kg/mObesity surgery · 2020Pooled it
- Changes in Time of Gastric Emptying After Surgical and Endoscopic Bariatrics and Weight Loss: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Pooled it
- Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis.Obesity surgery · 2017Pooled it
- Gastrointestinal Uses of Botulinum Toxin.Handbook of experimental pharmacology · 2021Trial
- EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial.Obesity surgery · 2019Trial
- Effects of Intraparietal Gastric Botulinum Toxin-A Injection on Weight Loss: A Retrospective Study of 500 Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Intragastric botulinum toxin injection for weight loss: current trends, shortcomings and future perspective.Clinical endoscopy · 2025Review
- Iatrogenic botulism after intragastric botulinum neurotoxin injections - a major outbreak.Neurological research and practice · 2024Article
- Intragastric botulinum toxin injection: a promising alternative for obesity treatment?Archives of medical science : AMS · 2024Article
- Lessons from a recent multicountry iatrogenic botulism outbreak.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Botulinum Toxin A Use in the Gastrointestinal Tract: A Reappraisal After Three Decades.Gastroenterology & hepatology · 2023Article
- Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study).Journal of clinical medicine · 2022Article
- Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications.Nutrients · 2021Review
- Gastric Botulinum Toxin-A Application for Weight Loss Therapy.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Devices and Endoscopic Bariatric Therapies for Obesity.Current obesity reports · 2018Review
- Response to "The Forgotten Fundus-Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis".Obesity surgery · 2018Article
- The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment.Obesity surgery · 2017Review
- Botulinum Toxin A for Controlling Obesity.Toxins · 2016Review
- Endoscopic Devices for Obesity.Current obesity reports · 2016Review
- Gastrointestinal traits: individualizing therapy for obesity with drugs and devices.Gastrointestinal endoscopy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsGastric injections of botulinum toxin A (BTA) have been reported to delay gastric emptying, increase satiation, and reduce body weight, but there are few data from randomized, placebo-controlled studies.
methodsWe enrolled 60 obese participants in a 24-week, double-blind, randomized, placebo-controlled, concealed allocation trial to compare the effects of gastric antral injections of BTA (100, 300, or 500 U) and saline placebo. The study was conducted at an outpatient clinical research unit. Participants were given one set of injections of BTA or placebo into the gastric antral muscularis propria by using endoscopic ultrasound guidance. Gastric emptying of solids was measured by scintigraphy; we also measured body weight, satiation (maximum tolerated volume in a caloric liquid drink test), calorie intake (by food frequency questionnaire), gastrointestinal symptoms, and psychological aspects of eating behavior (by rating scale).
resultsCompared with baseline values, 2 weeks after injections, the mean half-time for gastric emptying of solids increased by 0.8, 14, 24, and 14 minutes among subjects given placebo, 100, 300, or 500 U BTA, respectively (P = .24 overall, P = .04 for the group given 300 U vs placebo); 16 weeks after the injections, mean body weights were reduced by 2.2, 0.2, 2.3, and 3.0 kg in these groups, respectively. There were no statistically significant differences in mean body weight change, satiation volume, caloric intake, gastrointestinal symptoms, or psychological aspects of eating behavior among groups.
conclusionsGastric antral injections of BTA may delay gastric emptying at a dose of 300 U but do not cause early satiety, altered eating behaviors, or loss of body weight. Clinicaltrials.gov identifier: NCT00976443.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.